Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Hewlett Packard Enterprise Co (HPE) vs Novavax Inc (NVAX) Price & Performance

Hewlett Packard Enterprise CoTrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

Hewlett Packard Enterprise Co vs Novavax Inc — how do they compare? Hewlett Packard Enterprise Co trades at $48.96 (market cap $59.01B), while Novavax Inc trades at $8.08 (market cap $1.30B). The key difference: Hewlett Packard Enterprise Co is far larger — about 45.4× Novavax Inc's market cap, and Hewlett Packard Enterprise Co pays a 1.28% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.

HPENVAX
Market Cap
$59.01B$1.30B
Sector
TechnologyHealth
52-Week High
$56.14$11.19
52-Week Low
$19.81$6.22
Enterprise Value
$74.96B$800.50M
Dividend Yield
1.28%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Hewlett Packard Enterprise Co

HPE trades at $46.73, up 1.99% today, with a bullish technical signal and strong recent earnings beats. The stock is supported by a $6.3 billion AI backlog and a strategic shift toward high-margin networking, which now drives 44% of segment profit. Revenue grew to $34.3 billion in 2025, though net income fell sharply to $57 million due to heavy investment. Analysts maintain a consensus price target of $69.69, implying significant upside.

Outlook is positive given AI infrastructure demand and networking momentum, but risks include execution on large investments, competitive pressures, and volatile cash flows. The stock offers growth potential if margin expansion continues, yet investors must monitor debt levels and earnings consistency amid macroeconomic uncertainty.

Novavax Inc

Novavax (NVAX) trades at $8.08, down 1.64% on the day, with a bearish technical signal but strong recent earnings beats. The company reported $1.12B revenue in 2025 with a net income of $440.30M, though 2026 projections show a return to losses. Analyst consensus is bullish with a $14.00 price target, but negative shareholder equity and cash flow concerns persist.

Outlook remains mixed: strong valuation ratios and analyst support suggest upside potential, but negative cash flows, high liabilities, and projected 2026 losses pose significant risks. Investor sentiment is cautious amid recent stock declines and shareholder dissent highlighted in recent news.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Hewlett Packard Enterprise Co

Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment.

Read more on HPE

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX